ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,67%
Bitcoin
66 969,03
2,65%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Calliditas Therapeutics Ab (0A5R)

  7. Calliditas Therapeutics Ab (0A5R) Actualités

0A5R

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0A5R
DateHeureSourceTitreSymboleSociété
18/08/202310h21PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
17/08/202307h29PR Newswire (US)Interim Report Q2, 2023: Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
15/08/202310h52PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
13/07/202308h20PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
21/06/202310h12PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
30/05/202316h18PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
16/05/202307h17PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/202315h01PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
28/04/202310h54PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
27/04/202304h40PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
31/03/202317h24PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
13/03/202304h15PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
23/02/202307h41PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
02/02/202309h46PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
31/01/202308h22PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
30/12/202209h03PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
21/12/202204h08PR Newswire (US)Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022LSE:0A5RCalliditas Therapeutics Ab
13/12/202209h04PR Newswire (US)Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in JapanLSE:0A5RCalliditas Therapeutics Ab
09/12/202208h10PR Newswire (US)Calliditas to host fireside chat with its China commercial partner, Everest MedicinesLSE:0A5RCalliditas Therapeutics Ab
15/11/202208h45PR Newswire (US)Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPALSE:0A5RCalliditas Therapeutics Ab
14/11/202207h13PR Newswire (US)Calliditas Therapeutics: Interim Report Q3, 2022LSE:0A5RCalliditas Therapeutics Ab
07/11/202209h15PR Newswire (US)Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment LandscapeLSE:0A5RCalliditas Therapeutics Ab
21/10/202210h27PR Newswire (US)Calliditas Therapeutics' nomination committee composition for the AGM 2023LSE:0A5RCalliditas Therapeutics Ab
19/10/202216h09PR Newswire (US)Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
20/09/202215h29PR Newswire (US)Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
18/08/202207h18PR Newswire (US)Calliditas Therapeutics: Interim Report Q2, 2022LSE:0A5RCalliditas Therapeutics Ab
15/07/202217h19PR Newswire (US)European Commission approves Kinpeygo® for adults with primary IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
11/07/202213h00PR Newswire (US)Calliditas announces additions to the management teamLSE:0A5RCalliditas Therapeutics Ab
29/06/202200h27PR Newswire (US)Calliditas Therapeutics establishes a U.S. At-the-Market ProgramLSE:0A5RCalliditas Therapeutics Ab
19/05/202214h44PR Newswire (US)Calliditas receives positive CHMP opinion in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
 Showing the most relevant articles for your search:LSE:0A5R

Dernières Valeurs Consultées

TSX
HFPC.U
Helios Fairfax Partners
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés